CyberKnife Market Report Scope & Overview:

The CyberKnife Market was valued at USD 750.95 Million in 2025 and is expected to reach USD 3,810.38 Million by 2035, growing at a CAGR of 17.67% from 2026 to 2035.

The global CyberKnife market is experiencing exceptional growth, driven by the surging global cancer burden, the rising preference for non-invasive and minimally disruptive radiation therapy, and the continuous technological advancement of robotic radiosurgery platforms. CyberKnife is a non-invasive robotic radiosurgery system manufactured by Accuray Incorporated that delivers precisely targeted beams of high-dose radiation to tumours anywhere in the body with sub-millimetre accuracy. It achieves this precision by combining a compact linear accelerator mounted on a robotic arm with real-time imaging guidance that tracks and compensates for tumour and patient motion during treatment, enabling dose delivery that conventional radiotherapy platforms cannot match. With more than 19.3 million new cancer diagnoses recorded globally in 2023, the demand for precise, effective, and patient-friendly treatment modalities has grown dramatically.

In January 2025, Accuray Incorporated secured approval from China's National Medical Products Administration for both its Radixact SynC and CyberKnife S7 Systems, introducing enhanced adaptive delivery capabilities and advanced imaging features to one of the world's largest and fastest-growing healthcare markets. The NMPA approval enables Accuray to expand its installed base in China through direct commercial distribution, creating access to a patient population with extraordinary oncology treatment demand from an estimated 4.82 million new cancer diagnoses occurring annually in the country.

Market Size and Forecast

• Market Size in 2026E: USD 883.64 Million

• Market Size by 2035: USD 3,810.38 Million

• CAGR: 17.67% from 2026 to 2035

• Fastest Growing Region: Latin America

• Largest Region: North America

To Get More Information On CyberKnife Market - Request Free Sample Report

CyberKnife Market Trends

• Artificial intelligence integration in CyberKnife treatment planning is improving dose optimization, reducing planning time, and increasing treatment efficiency across radiation oncology centers

• Growing adoption of stereotactic body radiation therapy (SBRT) for oligometastatic disease is expanding the use of CyberKnife systems beyond primary tumor treatment into advanced cancer management applications

• Rising development of outpatient radiosurgery centers is supporting CyberKnife deployment by enabling cost-effective, non-invasive treatment delivery without hospitalization or anesthesia requirements

• Expansion of CyberKnife applications into neurological and functional disorders, including trigeminal neuralgia, arteriovenous malformations, epilepsy, and movement disorders, is broadening the clinical use of the technology

• Increasing medical tourism in emerging healthcare destinations such as India, Southeast Asia, and Latin America is driving investments in advanced CyberKnife systems to attract international patients and enhance treatment capabilities

U.S. CyberKnife Market Outlook

The U.S. CyberKnife Market was valued at approximately USD 223.28 Million in 2025 and is expected to reach approximately USD 1,135.56 Million by 2035, growing at a CAGR of approximately 18.33%.

The U.S. is the world's most commercially significant CyberKnife market within North America's dominant regional position. Accuray Incorporated's domestic commercial operations, supported by approximately 400 CyberKnife installations across U.S. academic medical centres, community cancer programmes, and freestanding radiation oncology centres, define the domestic commercial landscape. The American Cancer Society's projection of approximately 1.96 million new cancer diagnoses in the U.S. annually creates extraordinary and expanding clinical demand for precision radiosurgery. Medicare and commercial insurance reimbursement for CyberKnife SBRT and SRS procedures across prostate, lung, brain, spine, and hepatic indications removes the financial access barrier for the majority of patients, creating procedure volume that sustains system utilisation and drives replacement and expansion procurement.

In August 2024, Apollo Cancer Centre in Bengaluru, India installed South Asia's first CyberKnife S7 FIM Robotic Radiosurgery System, cementing its position as a regional hub for advanced cancer care and demonstrating the commercial momentum of CyberKnife adoption in Asia Pacific's most commercially dynamic emerging oncology markets. The installation reflects both the growing cancer treatment investment by major Indian hospital networks and the international patient attraction strategy that distinguishes Apollo's oncology brand across South Asian medical tourism markets.

CyberKnife Market Segment Analysis

• By Application, The Cancer segment dominated the CyberKnife Market with 40.8% share in 2025, while the Vascular Malformation segment is the fastest growing.

• By Treatment Type, The Tumour segment dominated the market with 32.0% share in 2025, while the Others segment is the fastest growing.

• By End Use, The Hospitals segment dominated the CyberKnife Market with 47.2% share in 2025, while the Outpatient Facilities segment is the fastest growing.

By Application, cancer dominates, vascular malformation grows fastest

The Cancer segment retained the dominant application position with approximately 40.8% of the CyberKnife market in 2025. Cancer's commercial primacy reflects the extraordinary and growing global disease burden whose 19.3 million annual new diagnoses create a clinical demand base that no other CyberKnife application category approaches in scale. Prostate cancer's adoption of CyberKnife SBRT as a clinically validated definitive treatment with published five-year outcome data, brain metastasis radiosurgery's systematic expansion as systemic therapy extends survival creating growing cumulative brain disease burden, and lung SBRT's position as the standard of care for medically inoperable early stage non-small cell lung cancer collectively sustain the Cancer segment's dominant commercial position. Accuray's clinical outcomes database across more than 5,000 installed CyberKnife systems worldwide creates the evidence foundation that oncologist confidence in cancer treatment requires.

Vascular malformation is the fastest growing application segment because advancements in CyberKnife precision delivery, accumulated clinical outcome data for arteriovenous malformation obliteration, and the growing neurosurgical recognition of radiosurgery as the preferred treatment for unresectable and deep-seated AVMs create structured above-average adoption growth. Each newly diagnosed AVM patient whose lesion location, eloquent cortex proximity, or patient surgical risk profile makes microsurgery high-risk creates a CyberKnife treatment referral whose volume grows with neurovascular diagnostic imaging improvement detecting previously undiagnosed vascular anomalies. The October 2022 Japanese Ministry of Health reimbursement approval for CyberKnife in trigeminal neuralgia demonstrates the expanding regulatory recognition of non-oncological CyberKnife applications that creates new reimbursement-supported growth avenues.

By End Use, hospitals dominate, outpatient facilities grow fastest

Hospitals retained the dominant end-use position with approximately 47.2% of the CyberKnife market in 2025. The hospital segment's commercial primacy reflects the multidisciplinary infrastructure that complex CyberKnife cases require. Brain radiosurgery cases requiring neurosurgical consultation, spinal radiosurgery cases requiring neuroradiological expertise, and head-and-neck cancer cases requiring multidisciplinary tumour board review collectively create clinical care pathways that the comprehensive hospital environment uniquely supports. Hospitals also benefit from academic credentialing environments that support clinical trial participation, government grant funding, and the publication of outcomes data that sustains institutional CyberKnife programme reputation and referral network development. Each academic medical centre whose CyberKnife programme creates regional referral relationships with community oncologists creates a sustainable high-volume treatment programme whose patient throughput sustains system cost-effectiveness.

Outpatient facilities are the fastest growing end use because the transition toward ambulatory oncology care, supported by CyberKnife's inherently outpatient-compatible treatment protocol, creates commercial investment momentum in freestanding radiation oncology centres and cancer clinic installations. Each prostate cancer patient whose five-fraction CyberKnife SBRT protocol requires no hospital admission creates outpatient centre procurement motivation whose economics improve as treatment volumes scale. Private equity investment in freestanding radiation oncology networks, whose returns depend on high-volume outpatient procedure delivery at lower fixed cost than hospital-based programmes, is creating systematic outpatient CyberKnife centre development investment that sustains the segment's fastest-growing designation.

Regional Analysis

North America CyberKnife Market Insights

North America dominated the global CyberKnife market in 2025, driven by high cancer incidence, strong reimbursement for CyberKnife SBRT and SRS procedures, advanced oncology infrastructure, and above-average physician awareness of stereotactic radiosurgery's clinical advantages. The United States accounts for approximately 84.6% of North American revenues through its approximately 400 CyberKnife installations across academic medical centres, community cancer programmes, and freestanding radiation oncology facilities whose combined procedure volume defines the global benchmark for CyberKnife clinical utilisation.

Canada contributes approximately 15.4% of North American revenues through its academic oncology centre CyberKnife programmes at the Princess Margaret Cancer Centre, BC Cancer, and major provincial cancer agencies whose publicly funded healthcare system creates structured capital equipment procurement through provincial cancer programme investment cycles.

Get Customized Report as Per Your Business Requirement - Enquiry Now

Europe CyberKnife Market Insights

Europe is a technically sophisticated CyberKnife market where the rising cancer burden of approximately 3.7 million new cases annually, growing physician acceptance of SBRT and SRS techniques, and increasing healthcare expenditure on advanced radiation therapy create consistent above-average procurement. Germany accounts for approximately 22.3% of European revenues through its academic university hospital network's CyberKnife installations, the aging population's above-average cancer incidence, and Heidelberg University Hospital's June 2024 Radixact System investment demonstrating the continuing German academic oncology community's advanced radiotherapy technology commitment.

The United Kingdom, France, and Italy are significant secondary markets where NHS cancer centre capital investment programmes, Institut Gustave Roussy's advanced radiotherapy leadership, and the Italian national health system's radiation oncology infrastructure investment create consistent CyberKnife procurement. Accuray's European commercial organisation sustains regional clinical and technical support from established country-level presences.

Asia Pacific CyberKnife Market Insights

Asia Pacific is a rapidly expanding CyberKnife market, driven by China's extraordinary cancer burden of approximately 4.82 million annual new diagnoses, India's growing private hospital network investment in premium oncology technology, Japan's established CyberKnife adoption supported by national health insurance reimbursement, and South Korea's advanced radiation oncology infrastructure. China accounts for approximately 44.8% of Asia Pacific revenues, with the January 2025 NMPA approval of the CyberKnife S7 and Radixact SynC Systems creating the regulatory foundation for accelerated commercial expansion in the world's largest cancer patient population.

India represents the most commercially dynamic emerging market within Asia Pacific where Apollo Hospitals, Fortis Healthcare, and Manipal Group's private oncology network investment creates above-average CyberKnife installation procurement. The August 2024 Apollo Cancer Centre Bengaluru CyberKnife S7 FIM installation demonstrates the private hospital sector's premium oncology technology strategy that sustains growing Indian CyberKnife procurement.

MEA & Latin America CyberKnife Market Insights

Latin America is the fastest growing regional CyberKnife market, driven by more than 1.5 million annual cancer cases in 2025, growing healthcare expenditure, and medical tourism attraction. Brazil leads Latin American revenues at approximately 44.2% through its public and private oncology network investment and the growing medical tourism sector attracting international cancer patients. Saudi Arabia leads MEA revenues at approximately 31.2% through Vision 2030 hospital investment and King Faisal Specialist Hospital's oncology programme. Kenya's September 2023 Kenyatta University first CyberKnife installation in Sub-Saharan Africa demonstrates expanding MEA access investment sustained through 2035.

Market Dynamics

Growth Drivers: Rising global cancer burden and growing clinical adoption of stereotactic radiosurgery as a non-invasive surgery alternative

The rising global cancer burden is the CyberKnife market's most commercially certain structural growth driver. The WHO's projection of 35 million new cancer cases annually by 2050, representing an 80% increase from the 2022 baseline, creates an extraordinary long-duration demand expansion for precision radiation therapy whose clinical advantage in patient experience, treatment duration, and precision creates growing specification preference over conventional surgery and fractionated radiotherapy in appropriate cases. Each new cancer diagnosis in a patient whose tumour location, medical comorbidities, or personal preference creates surgical or conventional radiotherapy contraindication creates a CyberKnife treatment candidate whose aggregate across global oncology practice sustains above-average market growth independent of technology adoption rate improvement.

Growing clinical adoption of stereotactic radiosurgery and stereotactic body radiation therapy as first-line and adjuvant treatment options creates structured procurement growth beyond simple cancer incidence growth. Each published clinical trial demonstrating CyberKnife SBRT equivalence or superiority to surgery for a new indication creates oncologist awareness that expands the referred patient population. The PACE-B trial's demonstration of prostate SBRT efficacy, the RTOG 0813 lung SBRT outcomes data, and accumulating spinal radiosurgery publications collectively create the evidence foundation that sustains growing physician adoption across oncology specialties.

Restraints: High system acquisition and maintenance cost and limited accessibility in developing healthcare markets

The high initial acquisition cost of a CyberKnife system, ranging from USD 4 million to USD 6 million for equipment alone before facility construction, installation, and commissioning costs, creates significant procurement barriers for small hospitals and healthcare institutions in cost-constrained environments. Each community hospital or regional cancer centre whose capital budget does not support CyberKnife acquisition creates a gap in geographic access to precision radiosurgery that moderates overall procedure volume growth below the rate that unrestricted access would create. The ongoing annual maintenance and service contract cost, typically ranging from USD 400,000 to USD 800,000 annually, creates an operating cost obligation that sustains financial pressure on institutions whose procedure volume does not generate sufficient reimbursement to achieve programme cost-effectiveness.

Limited accessibility in developing healthcare markets, where radiotherapy infrastructure of any kind remains scarce across sub-Saharan Africa, rural South Asia, and low-income Southeast Asian countries, creates a geographic disparity in CyberKnife access that moderates global market penetration below the rate that high-income market adoption alone would suggest. Each country whose radiotherapy resource gap is measured in basic linear accelerators rather than CyberKnife creates an adoption prerequisite that development assistance, international health organisation investment, and government capital programmes must address before CyberKnife commercial procurement becomes feasible.

Opportunities: Expansion into functional neurological disorder treatment and emerging economy cancer centre investment

Expansion into functional neurological disorder treatment represents the most commercially transformative near-term clinical opportunity for the CyberKnife market. Trigeminal neuralgia, whose drug-refractory presentations create surgical or radiosurgery treatment candidates, arteriovenous malformation obliteration, epilepsy surgery alternatives, and movement disorder treatment through thalamotomy are collectively creating a non-oncological treatment category whose regulatory approval and reimbursement coverage is progressively expanding. Each new regulatory approval or insurance coverage determination for a functional disorder CyberKnife indication creates a structured treatment referral pathway from neurology and neurosurgery practices whose patient volume compounds with the growing neurological disorder prevalence in aging global populations.

Emerging economy cancer centre investment represents the most commercially significant geographic expansion opportunity. Governments and private hospital groups in India, China, Brazil, Saudi Arabia, and Indonesia are systematically investing in advanced oncology infrastructure whose CyberKnife specification creates premium treatment capability that attracts both domestic and international patients. Each new cancer centre in an emerging economy whose clinical differentiation strategy specifies CyberKnife as the advanced radiosurgery platform creates procurement that compounds with the extraordinary pace of cancer treatment infrastructure investment across these high-growth healthcare markets.

Recent Developments:

• 2025: Accuray Incorporated secured approval from China's National Medical Products Administration in January 2025 for its Radixact SynC and CyberKnife S7 Systems, introducing enhanced adaptive delivery capabilities and imaging features to one of the world's largest healthcare markets with approximately 4.82 million annual new cancer diagnoses.

• 2024: Apollo Cancer Centre in Bengaluru installed South Asia's first CyberKnife S7 FIM Robotic Radiosurgery System in August 2024, establishing the facility as a regional hub for precision radiosurgery and demonstrating the private Indian hospital sector's commitment to premium oncology technology investment that attracts both domestic and international patients.

• 2024: Heidelberg University Hospital in Germany invested in the Accuray Radixact System in June 2024, enhancing cancer patient care with advanced radiation therapy technology and demonstrating the continuing commitment of leading European academic oncology centres to Accuray's precision radiotherapy platforms.

• 2023: Kenyatta University Teaching, Referral, and Research Hospital in Kenya commissioned the first CyberKnife radiotherapy system in Sub-Saharan Africa in September 2023, advancing access to high-precision cancer treatment for patients across East Africa who previously had no domestic access to stereotactic radiosurgery capability.

• 2023: Accuray Incorporated launched the CyberKnife Academia training programme in South Asia in 2023, providing structured clinical and technical training for radiation oncologists and medical physicists at newly installed CyberKnife centres, addressing the specialised expertise requirement that limits rapid clinical programme development following system installation.

CyberKnife Market Key Players

• Accuray Incorporated

• Varian Medical Systems (Siemens Healthineers)

• Elekta AB

• ViewRay Inc.

• Mevion Medical Systems Inc.

• IBA (Ion Beam Applications) SA

• Hitachi Ltd.

• Mitsubishi Electric Corporation

• Shinva Medical Instrument Co. Ltd.

• Huiheng Medical Inc.

• Neusoft Medical Systems Co. Ltd.

• Brainlab AG

• RaySearch Laboratories AB

• Philips Healthcare

• GE HealthCare Technologies Inc.

• Siemens Healthineers AG

• Canon Medical Systems Corporation

• Best Theratronics Ltd.

• Isoray Inc.

• Panacea Medical Technologies Pvt. Ltd

CyberKnife Market Report Scope: